CD274 and head and neck squamous cell carcinoma: Overall, these studies indicate that high TMB predicts improved benefit from checkpoint inhibition in HNSCC but the lack of a consistent threshold and correlation with other biomarkers such as PD-L1 expression preclude its use as a single biomarker.